PMC:7161517 / 32702-33100 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T196","span":{"begin":74,"end":79},"obj":"Body_part"},{"id":"T197","span":{"begin":93,"end":98},"obj":"Body_part"},{"id":"T198","span":{"begin":301,"end":307},"obj":"Body_part"}],"attributes":[{"id":"A196","pred":"fma_id","subj":"T196","obj":"http://purl.org/sig/ont/fma/fma7088"},{"id":"A197","pred":"fma_id","subj":"T197","obj":"http://purl.org/sig/ont/fma/fma7088"},{"id":"A198","pred":"fma_id","subj":"T198","obj":"http://purl.org/sig/ont/fma/fma9637"}],"text":"Several societies, including the American College of Cardiology, American Heart Association, Heart Failure Society of America (68), and European Society of Cardiology (69) have recommended continuing RAS antagonists because of the lack of conclusive data on a link between upregulation of systemic or tissue ACE2 and the increased susceptibility to COVID-19 in patients with cardiovascular disease."}

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T86","span":{"begin":74,"end":79},"obj":"Body_part"},{"id":"T87","span":{"begin":93,"end":98},"obj":"Body_part"},{"id":"T88","span":{"begin":200,"end":203},"obj":"Body_part"},{"id":"T89","span":{"begin":301,"end":307},"obj":"Body_part"}],"attributes":[{"id":"A86","pred":"uberon_id","subj":"T86","obj":"http://purl.obolibrary.org/obo/UBERON_0000948"},{"id":"A87","pred":"uberon_id","subj":"T87","obj":"http://purl.obolibrary.org/obo/UBERON_0000948"},{"id":"A88","pred":"uberon_id","subj":"T88","obj":"http://purl.obolibrary.org/obo/UBERON_0018229"},{"id":"A89","pred":"uberon_id","subj":"T89","obj":"http://purl.obolibrary.org/obo/UBERON_0000479"}],"text":"Several societies, including the American College of Cardiology, American Heart Association, Heart Failure Society of America (68), and European Society of Cardiology (69) have recommended continuing RAS antagonists because of the lack of conclusive data on a link between upregulation of systemic or tissue ACE2 and the increased susceptibility to COVID-19 in patients with cardiovascular disease."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T182","span":{"begin":93,"end":106},"obj":"Disease"},{"id":"T183","span":{"begin":349,"end":357},"obj":"Disease"},{"id":"T184","span":{"begin":375,"end":397},"obj":"Disease"}],"attributes":[{"id":"A182","pred":"mondo_id","subj":"T182","obj":"http://purl.obolibrary.org/obo/MONDO_0005252"},{"id":"A183","pred":"mondo_id","subj":"T183","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A184","pred":"mondo_id","subj":"T184","obj":"http://purl.obolibrary.org/obo/MONDO_0004995"}],"text":"Several societies, including the American College of Cardiology, American Heart Association, Heart Failure Society of America (68), and European Society of Cardiology (69) have recommended continuing RAS antagonists because of the lack of conclusive data on a link between upregulation of systemic or tissue ACE2 and the increased susceptibility to COVID-19 in patients with cardiovascular disease."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T315","span":{"begin":74,"end":79},"obj":"http://purl.obolibrary.org/obo/UBERON_0000948"},{"id":"T316","span":{"begin":74,"end":79},"obj":"http://purl.obolibrary.org/obo/UBERON_0007100"},{"id":"T317","span":{"begin":74,"end":79},"obj":"http://purl.obolibrary.org/obo/UBERON_0015228"},{"id":"T318","span":{"begin":74,"end":79},"obj":"http://www.ebi.ac.uk/efo/EFO_0000815"},{"id":"T319","span":{"begin":93,"end":98},"obj":"http://purl.obolibrary.org/obo/UBERON_0000948"},{"id":"T320","span":{"begin":93,"end":98},"obj":"http://purl.obolibrary.org/obo/UBERON_0007100"},{"id":"T321","span":{"begin":93,"end":98},"obj":"http://purl.obolibrary.org/obo/UBERON_0015228"},{"id":"T322","span":{"begin":93,"end":98},"obj":"http://www.ebi.ac.uk/efo/EFO_0000815"},{"id":"T323","span":{"begin":258,"end":259},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"}],"text":"Several societies, including the American College of Cardiology, American Heart Association, Heart Failure Society of America (68), and European Society of Cardiology (69) have recommended continuing RAS antagonists because of the lack of conclusive data on a link between upregulation of systemic or tissue ACE2 and the increased susceptibility to COVID-19 in patients with cardiovascular disease."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T336","span":{"begin":200,"end":203},"obj":"Chemical"},{"id":"T337","span":{"begin":204,"end":215},"obj":"Chemical"}],"attributes":[{"id":"A336","pred":"chebi_id","subj":"T336","obj":"http://purl.obolibrary.org/obo/CHEBI_63620"},{"id":"A337","pred":"chebi_id","subj":"T337","obj":"http://purl.obolibrary.org/obo/CHEBI_48706"}],"text":"Several societies, including the American College of Cardiology, American Heart Association, Heart Failure Society of America (68), and European Society of Cardiology (69) have recommended continuing RAS antagonists because of the lack of conclusive data on a link between upregulation of systemic or tissue ACE2 and the increased susceptibility to COVID-19 in patients with cardiovascular disease."}

{"project":"LitCovid-sentences","denotations":[{"id":"T196","span":{"begin":0,"end":398},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Several societies, including the American College of Cardiology, American Heart Association, Heart Failure Society of America (68), and European Society of Cardiology (69) have recommended continuing RAS antagonists because of the lack of conclusive data on a link between upregulation of systemic or tissue ACE2 and the increased susceptibility to COVID-19 in patients with cardiovascular disease."}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T51","span":{"begin":93,"end":106},"obj":"Phenotype"},{"id":"T52","span":{"begin":375,"end":397},"obj":"Phenotype"}],"attributes":[{"id":"A51","pred":"hp_id","subj":"T51","obj":"http://purl.obolibrary.org/obo/HP_0001635"},{"id":"A52","pred":"hp_id","subj":"T52","obj":"http://purl.obolibrary.org/obo/HP_0001626"}],"text":"Several societies, including the American College of Cardiology, American Heart Association, Heart Failure Society of America (68), and European Society of Cardiology (69) have recommended continuing RAS antagonists because of the lack of conclusive data on a link between upregulation of systemic or tissue ACE2 and the increased susceptibility to COVID-19 in patients with cardiovascular disease."}

{"project":"LitCovid-PMC-OGER-BB","denotations":[{"id":"T1051","span":{"begin":53,"end":63},"obj":"UBERON:0000948"},{"id":"T1052","span":{"begin":74,"end":79},"obj":"UBERON:0000948"},{"id":"T1053","span":{"begin":93,"end":98},"obj":"UBERON:0000948"},{"id":"T1054","span":{"begin":156,"end":166},"obj":"UBERON:0000948"},{"id":"T1055","span":{"begin":301,"end":307},"obj":"UBERON:0000479"},{"id":"T1056","span":{"begin":308,"end":312},"obj":"G_3;PG_10;PR:000003622"},{"id":"T1057","span":{"begin":349,"end":357},"obj":"SP_7"},{"id":"T1058","span":{"begin":375,"end":389},"obj":"UBERON:0004535"},{"id":"T56","span":{"begin":375,"end":389},"obj":"UBERON:0004535"},{"id":"T17759","span":{"begin":53,"end":63},"obj":"UBERON:0000948"},{"id":"T7351","span":{"begin":74,"end":79},"obj":"UBERON:0000948"},{"id":"T73963","span":{"begin":93,"end":98},"obj":"UBERON:0000948"},{"id":"T87034","span":{"begin":156,"end":166},"obj":"UBERON:0000948"},{"id":"T40873","span":{"begin":301,"end":307},"obj":"UBERON:0000479"},{"id":"T70153","span":{"begin":308,"end":312},"obj":"G_3;PG_10;PR:000003622"},{"id":"T30590","span":{"begin":349,"end":357},"obj":"SP_7"},{"id":"T5335","span":{"begin":375,"end":389},"obj":"UBERON:0004535"}],"text":"Several societies, including the American College of Cardiology, American Heart Association, Heart Failure Society of America (68), and European Society of Cardiology (69) have recommended continuing RAS antagonists because of the lack of conclusive data on a link between upregulation of systemic or tissue ACE2 and the increased susceptibility to COVID-19 in patients with cardiovascular disease."}

{"project":"LitCovid-PubTator","denotations":[{"id":"1361","span":{"begin":308,"end":312},"obj":"Gene"},{"id":"1367","span":{"begin":361,"end":369},"obj":"Species"},{"id":"1372","span":{"begin":349,"end":357},"obj":"Disease"},{"id":"1373","span":{"begin":375,"end":397},"obj":"Disease"}],"attributes":[{"id":"A1361","pred":"tao:has_database_id","subj":"1361","obj":"Gene:59272"},{"id":"A1367","pred":"tao:has_database_id","subj":"1367","obj":"Tax:9606"},{"id":"A1372","pred":"tao:has_database_id","subj":"1372","obj":"MESH:C000657245"},{"id":"A1373","pred":"tao:has_database_id","subj":"1373","obj":"MESH:D002318"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Several societies, including the American College of Cardiology, American Heart Association, Heart Failure Society of America (68), and European Society of Cardiology (69) have recommended continuing RAS antagonists because of the lack of conclusive data on a link between upregulation of systemic or tissue ACE2 and the increased susceptibility to COVID-19 in patients with cardiovascular disease."}